Piper Sandler lowered the firm’s price target on Prothena (PRTA) to $15 from $81 and keeps an Overweight rating on the shares. While the firm was disappointed to see PRX012’s ASCENT program hit non-competitive rates of ARIA, Piper is not concerned about Prothena as the company has a high-value partnership pipeline ripe for future cash opportunities. Firstly, the firm thinks it is crucial not to minimize the ASCENT data as it effectively supports PRX012’s mechanism and de-risks second generation, PRX012-TfR, with plans underway to seek potential partnership opportunities for both. Furthermore, Piper thinks there is a lot of value attached to Prothena’s robust partnership pipeline. That said, the firm removed PRX012 in AD from its model as it is viewing potential partnership as an upside.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
- Prothena Announces Promising Phase 1 Results for PRX012
- Prothena announces Novo Nordisk to advance coramitug into Phase 3
- Prothena’s Coramitug Advances to Phase 3 with Novo Nordisk
- Prothena’s Strategic Initiatives and Promising Alzheimer’s Pipeline Drive Buy Rating
- Prothena Reports Q2 2025 Financial Results and Pipeline Progress